High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsCurrent trends and intricacies in the management of HIV-associated pulmonary tuberculosisTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicityPopulation pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsVirological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.Update on opportunistic infections in the era of effective antiretroviral therapyThe safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.Metabolomic screening and identification of the bioactivation pathways of ritonavirCYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.Special populations and pharmacogenetic issues in tuberculosis drug development and clinical researchTB and HIV Therapeutics: Pharmacology Research Priorities.Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South AfricaWhen to start antiretroviral therapy during tuberculosis treatment?Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and RilpivirineHepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam.Management of individuals requiring antiretroviral therapy and TB treatment.Tuberculosis and HIV co-infection: screening and treatment strategies.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.The pharmacological challenges of treating tuberculosis and HIV coinfections.Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers.HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q24631021-894424B7-479F-44B7-B1E4-99ED28032030Q28069032-BA8BCF49-2DC7-434F-B70E-F7525B732066Q28087473-21291065-6B84-4262-8C02-C4D3ECAB2836Q31041943-8B8399AE-A7B0-47B4-BE46-3BDB15F1EF22Q33712438-2FA73362-15CA-4630-8CD4-A6B98EAF1000Q33839294-A19AFAC7-6AC7-48ED-8D08-B794206FA484Q34085853-884B6EE5-2C05-4F6D-AF7F-DC6D94C0F1E2Q34193050-769B5873-0400-494B-88DC-F22A7D598D30Q34427442-CDDD1BDE-24BF-4859-9854-34AF583EF9A4Q34455442-B063195B-C325-4823-8AFE-04B6FDB2EFA4Q35043048-B32FB8A1-6AC2-41DB-AE13-3474D586B472Q35065871-6FAA2EC7-6090-48E8-A6A1-619099EFBD65Q35626853-A08BCBBB-7AC5-44A7-8EA3-9806755B6723Q35647173-7FA2E945-3952-4E25-8EDD-5D0EC276C159Q36000004-0ADF69C1-6155-4F8A-A2CD-02B1A2DAC12CQ36099838-B211307A-9CF5-4EE5-B2D2-AF4782FA4269Q36111218-326DCCAF-AC34-41F1-991A-3A3752A74F22Q36709012-3B4D61DF-570D-41E5-9C0C-470075F2D92BQ36739450-83AF8CDD-4EC8-4E85-989B-CA9E2C0C291EQ36804433-A689F522-3EB6-4FAC-9F63-02A6B5598C37Q36888008-DB2B8E16-F03A-4978-B64D-B698220F06D9Q37121902-C790A4DE-8234-467D-9F6A-90DCC21D08B0Q37176147-E0B5E797-772E-4B87-A02E-7791ABF3599FQ37666456-53541B69-42B6-460C-B884-0C06A90E4333Q37895251-6F159D70-5A81-4654-98E5-61B2513F45E9Q38207924-8778C489-A4A9-4C44-BD50-73E13FF5FDAEQ38874266-B665EE93-F004-43A9-9B80-0EBAEFF80F63Q38927209-1141BAEF-02AE-4353-B3A7-18A2A5C679B6Q39003762-C805F980-4BDE-4FC6-8E83-8145037CA175Q42618217-0560AE66-9A49-4F73-9D0E-0889E027174AQ46488387-908D2AC4-A53F-4CAF-9A29-9E7E6F5AE66EQ57180790-910F5876-8512-4727-8464-A175F0FBA6A6
P2860
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
High incidence of adverse even ...... f lopinavir/ritonavir tablets.
@en
type
label
High incidence of adverse even ...... f lopinavir/ritonavir tablets.
@en
prefLabel
High incidence of adverse even ...... f lopinavir/ritonavir tablets.
@en
P2093
P1433
P1476
High incidence of adverse even ...... f lopinavir/ritonavir tablets.
@en
P2093
David M Burger
Gerard A Rongen
Hanneke M J Nijland
Martin J Boeree
Peter P Koopmans
Peter van Uden
Rafaëlla F A L'homme
Rob E Aarnoutse
P304
P356
10.1097/QAD.0B013E3282FAA71E
P407
P577
2008-05-01T00:00:00Z